Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

The fusion genes NRG1 and NRG2 , members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, NRG1 retains its EGF-like active domain, binds to the ERBB ligand family, and triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. CD74 and SLC3A2 are the most frequently observed fusion partners. RNA-based next-generation sequencing is the primary method for detecting NRG1 and NRG2 gene fusions, whereas pERBB3 immunohistochemistry can serve as a rapid prescreening tool for identifying NRG1 -positive patients. Currently, there are no approved targeted drugs for NRG1 and NRG2 . Common treatment approaches involve pan-ERBB inhibitors, small molecule inhibitors targeting ERBB2 or ERBB3, and monoclonal antibodies. Given the current landscape of NRG1 and NRG2 in solid tumors, a consensus among diagnostic and treatment experts is proposed, and clinical trials hold promise for benefiting more patients with NRG1 and NRG2 gene fusion solid tumors.


Introduction
Gene fusion caused by chromosomal rearrangement is a common event in solid tumors, driving tumorigenesis.The identification and targeting of fusion genes have been significant breakthroughs in medicine.Chromosomal rearrangements of receptor tyrosine kinases (RTKs) can generate oncogenic fusion protein kinases.Several tyrosine kinase inhibitors (TKIs) have been approved for treating solid malignancies with RTK fusions. 1 The epidermal growth factor (EGF) receptor family belongs to the type I RTK family.NRG1 and NRG2 genes encode neuroregulin 1 and 2 proteins, respectively, which are part of the EGF ligand family.NRG1 gene fusion activates and retains the EGF-like domain of the NRG1 protein, continuously binding to ERBB receptor family members (ERBB2 and ERBB4).This initiates intracellular signaling cascades, leading to sustained cell proliferation and tumorigenesis. 2 Although NRG1 gene fusion in solid tumors is rare (0.2%), patients with NRG1 fusion tumors often have a poor response to standard treatments.Disrupting NRG1 binding to ERBB3 or impacting ERBB2/ERBB3 heterodimerization can reduce the volume of NRG1 fusion tumors in various solid tumors. 3RG1 is an emerging oncogenic driver and a potential therapeutic target, but no approved targeted drugs are available for NRG1 fusion tumors.NRG2 fusion has also been found in lung adenocarcinoma patients, but further understanding of its biological functions is needed.4,5 This article summarizes the biological behaviors of NRG1 and NRG2 fusion-related proteins and introduces molecular characteristic data of NRG1 gene fusion in solid tumors from the largest-scale database.It proposes a screening strategy for NRG1/2 gene fusion solid tumors based on existing domestic resources.Ongoing clinical trials targeting NRG1 fusion solid tumors are also summarized, along with proposed treatment consensus.
The Biological Basis of the NRG1/2 Gene The Gene Structures and Biological Functions of the NRG1/2 Gene RTKs are essential in drug development, with the ERBB family, including ERBB1 (EGFR), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4), being transmembrane RTKs known as the EGF receptor family.The tyrosine kinase ligand family, which includes the neuregulin family (NRGs), consists of six protein isoforms: NRG1, NRG2, NRG3, NRG4, NRG5 (tomoregulin), and NRG6 (neuroglycan C).These ligands all contain an extracellular EGF-like domain that activates the ERBB RTK.They are crucial for the development of the nervous and cardiovascular systems. 6,7

NRG1
][10][11][12] NRG1 interacts with ERBB3 and ERBB4 through its EGF-like domain, tissue specificity, and immunoglobulin-like domain. 13NRG1 has multiple isoforms and structural differences, with six protein subtypes (I-VI) and at least 31 gene subtypes.The NRG1 protein consists of the EGF-like domain, the N-terminal sequence (type I, II, or III), and the C-terminal sequence (transmembrane or not).Type I and II NRGs are also referred to as "Ig-NRGs," whereas type III NRGs are known as "CRD-NRGs."The fusion-involved subtype of NRG1 belongs to type III and has a higher affinity for receptor binding than the α-type.This difference in binding affinity contributes to the oncogenic properties of NRG1 IIIβ compared with NRG1 IIIα.NRG1 is initially produced as a membrane-anchored precursor, and proteolysis releases the EGF-like domain, activating ERBB3 and ERBB4.The interaction between NRG1 and ERBB3 can lead to heterodimerization, particularly with ERBB2, facilitating downstream signaling pathways such as PI3K/AKT and MAPK.NRG1 can also interact with ERBB4, forming homodimers or heterodimers with ERBB2/ERBB3, further activating multiple pathways 14,15 (►Fig.1A).

NRG2
7][18] NRG2 has two isoforms, α and β, due to different splicing sites.Research has shown that NRG2β is a high-affinity ligand for ERBB4, strongly stimulating ERBB4 tyrosine phosphorylation.On the other hand, the splicing isoform NRG2α is a low-affinity ligand for ERBB4 and does not strongly stimulate ERBB4 phosphorylation 19 (►Fig.1B).

Fusion and Carcinogenic Mechanism of NRG1/2
The activation or overexpression of NRGs has been shown to regulate tumor cell growth, invasion, and angiogenesis.These genes are associated with various types of tumors including breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, gastric cancer, lung cancer, thyroid cancer, glioma, medulloblastoma, melanoma, and head and neck squamous cell carcinoma. 8,20,21In solid tumors, gene fusion is a significant driver mutation.Specifically, NRG1 gene fusion is considered a potential targetable oncogenic driver.The oncogenicity of NRG1 and NRG2 gene fusions relies on maintaining an intact EGF-like domain without frameshift mutations. 2Knockout mouse models with disrupted EGFlike domain (neuregulin ) have demonstrated that all NRG1 subtypes lose their function, leading to embryonic death due to cardiac and nervous system malformations. 22he discovery of NRG1 fusion dates back to 1997 in the breast cancer cell line MDA-MB-175, where it was identified as a tumor-specific DOC4-NRG1 transcript that promotes tumor cell proliferation. 23In lung cancer, NRG1 gene fusion results in the overexpression of the EGF-like domain of NRG1 on the cell surface.This enhances its binding ability with ERBB3, promoting heterodimerization of ERBB2/ERBB3 and subsequently activating downstream PI3K/AKT and MAPK signaling pathways. 24Studies using CD74-NRG1 transgenic mouse models have shown that the proliferation of CD74-NRG1 cells is carcinogenic and accompanied by increased protein transcription levels of ERBB2 and ERBB3, indicating that NRG1 gene fusion drives tumor development.gene fusion is the first potential therapeutic oncogenic driver mutation specifically associated with a subtype of lung adenocarcinoma and is predominantly found in nonsmoking patients, in contrast to the tobacco-associated KRAS gene mutation. 24In a transcriptome sequencing study of 25 neversmoking lung adenocarcinoma patients, one case of CD74-NRG1 gene fusion was identified in a patient with invasive mucinous subtype.Mechanistically, CD74-NRG1 gene fusion leads to extracellular expression of the EGF-like domain of NRG1 III-β3, providing a ligand for the ERBB2-ERBB3 receptor complex.Consequently, ERBB2 and ERBB3 are highly expressed in index cases, and phosphorylated ERBB3 is specifically expressed in fusion tumors (p < 0.0001).In lung cancer cell lines expressing ERBB2 and ERBB3, ectopic expression of CD74-NRG1 activates the ERBB3 and PI3K-AKT pathways, resulting in increased colony formation in soft agar. 26eakpoints on the NRG1 chromosome were discovered by Adélaïde et al in two pancreatic cancer cell lines (PaTu I, SUIT-2), indicating that NRG1 breakpoints may be a recurring phenomenon in solid tumors. 27Subsequent studies on breast cancer, pancreatic cancer, and lung cancer tumor samples further emphasized the role of NRG1 rearrangements in tumor development. 280][31][32] The identification of recurrent and potentially targetable NRG1 fusions provides therapeutic opportunities for these tumors.
In addition to NRG1 gene fusion, CD74-NRG2 gene fusion has been detected in lung adenocarcinoma patients.NRG2 has moderate affinity with ERBB2/4 heterodimers, and phosphorylation of ERBB2/3/4 may serve as an alternative biomarker for pathway activation. 33Immunohistochemical analysis of CD74-NRG2 samples showed moderate phosphorylation of ERBB4 in positive tumor cells, whereas EGFR, ERBB2, and ERBB3 did not show phosphorylation.On the other hand, ERBB family members were phosphorylated in NRG1 fusion tumor cells, suggesting that ERBB4 inhibitors may be effective drugs for NRG2 gene fusion tumors. 4idemiology of NRG1/2 Gene Fusion in Solid Tumors

Mutation Frequency of NRG1/2 Fusion
The occurrence rate of NRG1 and NRG2 gene fusion in solid tumors is extremely rare.The overall mutation frequency of NRG1 gene fusion in all solid tumors is approximately 0.2%, but in certain patient subgroups, the mutation frequency can be as high as 30%.A study in the United States found an occurrence rate of NRG1 gene fusion of 0.19% among 21,858 cases of solid tumors.The most common tumor types with NRG1 gene fusion are gallbladder cancer, pancreatic cancer, renal cell carcinoma, ovarian cancer, nonsmall cell lung cancer (NSCLC), breast cancer, sarcoma, and bladder cancer.The incidence rates of other tumor types are all less than 0.1%. 3Data from a population of solid tumor patients in Korea showed an occurrence rate of NRG1 gene fusion of 0.27%, with lung cancer being the most common tumor type. 34Another study based on data from 13,089 cases of NSCLC in China showed an occurrence rate of NRG1 gene fusion of 0.19%. 35IMA accounts for approximately 57 to 61% of NRG1 fusion NSCLC and slightly more than half of NRG1 fusion NSCLC patients have never smoked. 36,37he breakpoints of NRG1 fusion are typically found in three specific intronic regions: (1) a 47-kb region between exon 1 and exon 2; (2) a 955-kb region between exon II and exon 2; (3) a region between exon 5 and exon 6, including exon III, with a length of 111 kb. 36The occurrence rate of NRG2 fusion is even rarer, with a frequency 5 to 10 times lower than that of NRG1. 4,5,38sion Partners of NRG1 Gene Fusion NRG1 gene fusion can have different partners, which affects the biological properties of the synthesized chimeric protein.
The NRG1 protein has a domain similar to EGF and acts as a ligand for ERBB3.The ligand can be localized in the complex, while the partner provides a transmembrane domain that binds the ligand to the membrane.In most cases, the partner facilitates the interaction between the ligand and the ERBB3 protein on adjacent cells.CD74 and SLC3A2 are the most common upstream fusion partners, but other partner genes include ATP1B1, CDH1, CLU, CRADD, FUT10, INCENP, KIF22, RBPMS, SLC20A2, VWA8, and XKR6, among others. 34

Other Molecular Characteristics of NRG1 Gene Fusion
Multiple studies have consistently shown that NRG1 gene fusions are generally mutually exclusive with driver genes such as EGFR, ALK, and ROS1.This indicates that NRG1 gene fusion may act as a strong driver mutation promoting the occurrence and development of tumors.Co-occurring mutations with NRG1 gene fusions include TP53 (54.5%),KRAS, BRAF, PIK3CA, NF1, and NF2, among others. 3,34Among 15 patients with solid tumors harboring NRG1 gene fusions, the median tumor mutation burden was 3.9/Mb (range: 1.0-51.20/Mb),and the median microsatellite instability was 1.98% (range: 1.0-5.0%). 34e believe that NRG1 and NRG2 gene fusions are rare but important targetable oncogenic alterations.Ideally, all advanced and metastatic solid tumors should be systematically tested for NRG1 and NRG2 gene fusions, along with other actionable oncogenic drivers.Molecular testing should be performed at the time of diagnosis, especially for patients with a histopathological diagnosis of IMA.Considering the frequent breakpoints in the intronic region of the NRG1 gene, it is crucial to include intronic coverage when selecting the testing method, especially gene sequencing.

Detection of NRG1/2 Fusion
Chromosomal translocation is the primary cause of fusion genes, and accurate diagnosis of fusion genes is essential for effective treatment.In the clinical translation of NRG fusion α and β subtypes, it is crucial to avoid false negatives and minimize the need for further confirmation testing due to the diversity and rarity of NRG fusion variants.This requires advanced testing technology with high sensitivity.The standardization of operating procedures can improve the accuracy of detection. 38Additionally, considering the limited availability of resources in many countries, cost-effectiveness is also an important factor to consider in the testing method.To optimize screening, specific tumor samples and knowledge of NRG fusions in specific cancer types should be combined.Combining multiple testing methods can further enhance the accuracy and reliability of NRG1 fusion detection.

Immunohistochemistry
Immunohistochemistry (IHC) can indirectly detect the fusion status of NRG1 and NRG2 by detecting the protein expression levels of NRG1 or NRG2 and their fusion partners in tumor tissues.IHC has advantages such as fast turnaround time, low cost, high sensitivity, and strong specificity.It relies on specific antibodies that can identify fusion proteins in tumor tissues.However, the selection of antibodies can significantly impact the results, and not all fusion variants may be detectable by specific antibodies.
Indirect detection of pERBB3 immunostaining may serve as a powerful predictive marker for NRG1 fusion, as NRG1 fusion can lead to increased fusion products and chimeric ligands, resulting in ERBB2/ERBB3 heterodimerization and phosphorylation-mediated activation of the ERBB3 receptor. 26In a study cohort of 85 Caucasian patients, NRG1 rearrangements were investigated in 51 IMA patients and 34 non-IMA patients using NRG1 fluorescence in situ hybridization (FISH), pERBB3 immunohistochemistry, and RNA target sequencing.The findings revealed that 31% of IMA and 3% of non-IMA patients had NRG1 gene rearrangements, indicating that pERBB3 immunohistochemistry had a sensitivity of 94% and specificity of 100% in the 51 IMA samples, as well as a sensitivity of 100% and specificity of 94% in the 34 non-IMA adenocarcinoma samples.Additionally, CD74-NRG1 fusion transcripts were detected in 4 NRG1-positive IMA patients.Importantly, all IMA cases with abnormal pERBB3 expression exhibited NRG1 gene rearrangement. 39Furthermore, in a study involving 245 lung adenocarcinoma samples, pERBB3 immunohistochemical detection demonstrated a sensitivity of 100% and specificity of 97.5%. 26Thus, pERBB3 immunohistochemical detection may serve as a rapid and effective prescreening method for identifying NRG1-positive patients.

Fluorescence in Situ Hybridization
FISH is a widely utilized method for visualizing and confirming the presence of NRG1 and NRG2 fusions in paraffin-embedded tissue samples.This technique employs fluorescently labeled probes that specifically bind to the fusion genes, enabling precise localization and assessment of fusion events.FISH is particularly valuable in identifying the specific fusion partners and breakpoints involved.When there is a suspicion of NRG1 or NRG2 fusion with distinct characteristics, FISH can be employed for genotyping purposes.Break-apart FISH, a commonly employed clinical method and one of the Food and Drug Administration (FDA)-approved techniques for detecting ALK rearrangements, detects gene fusions.However, unlike ALK fusion FISH testing, the scoring criteria for determining NRG1 fusion positivity lack comprehensive study and validation.Consequently, the current criteria for NRG1 FISH testing positivity temporarily adopt the 15% separation signal threshold used in ALK testing, pending favorable validation data for widespread adoption of NRG1 FISH. 38While FISH testing has demonstrated success in NSCLC, 40 it was unable to detect NRG1 fusions in two out of three cases of KRAS wild type pancreatic ductal adenocarcinoma with complex NRG1 rearrangement patterns. 31In addition to its inability to detect complex rearrangement patterns, FISH has other limitations, such as the restricted ability to simultaneously test multiple targets and the inability to determine if fusion partners express fusion products or if other co-mutations are present.Therefore, due to its high cost, low sensitivity, and specificity, we do not recommend FISH as a routine screening method for NRG1 fusion detection.

RNA-Based Next-Generation Sequencing
Transcriptome sequencing using second-generation sequencing technology enables accurate identification of NRG1 and NRG2 fusions by comparing gene expression profiles between tumor and normal tissues.This method provides comprehensive information about fusion transcripts and can detect new fusion events.RNA-based next-generation sequencing (NGS) is the optimal tool for discovering fusion genes at the transcriptional level due to the chimeric nature of fusion transcripts.The frequency of NRG1 or NRG2 fusions can be calculated using the number of connected reads, including the β/α isoform ratio.However, RNA-based NGS has limitations in obtaining sufficient quality and quantity of RNA from clinical samples, especially formalin-fixed paraffin-embedded tissues.In the eNRGy1 clinical trial, a combination of DNA and/or RNA NGS and FISH was employed to identify NRG1 fusions.The detection rate of NRG1 fusion using RNA-based NGS was found to be 74% (81/110), whereas the detection rate using DNA-based NGS was only 26%.This highlights the superior advantages of RNA-based NGS in fusion detection. 37

Whole Transcriptome Sequencing
Whole transcriptome sequencing (WTS) is the most comprehensive method for detecting gene fusions, particularly in identifying new fusion partners.WTS directly sequences transcribed mRNA without relying on initial adapter ligation steps. 30,31,40,41Unlike targeted RNA sequencing, WTS does not require prior knowledge of fusion partners.However, WTS has limitations such as high requirements for sample quality and quantity, complex data analysis, high cost, and difficulty in detecting low-frequency events.

Targeted RNA-Sequencing Panel
Targeted RNA sequencing technology, such as anchored multiplex polymerase chain reaction (AMP), evaluates specific gene expression, mutations, and fusions and improves sequencing coverage by analyzing multiple genes in a single assay. 42,43AMP is commercially available but mainly targets genes like ALK, RET, and ROS1 and covers the NRG1 gene. 44owever, it cannot reliably detect NRG2 gene fusions due to the lack of specific primers for NRG2 gene amplification, which is a disadvantage compared with WTS. 3,38A-Based Next-Generation Sequencing DNA-based NGS technology is widely used for tumor and plasma gene typing.It is a high-throughput sequencing method that provides comprehensive genetic information with reduced costs and time.Hybrid capture technology, a commonly used method, enables the sequencing of translocation breakpoints.DNA-NGS technology can identify most NRG1 gene fusions and determine their breakpoints.However, it may miss fusions with large introns and cannot determine fusion protein functionality.Therefore, we recommend using a DNA gene testing panel that covers the intronic regions of NRG1 and NRG2 genes.

Reverse Transcription-Polymerase Chain Reaction
Reverse transcription-polymerase chain reaction is a reliable method for detecting fusion transcripts of NRG1 and NRG2 genes.It involves reverse transcription of RNA into cDNA, followed by amplification using fusion gene-specific primers.This method accurately detects fusion breakpoints and is commonly used for validation, especially for partner genes with a high fusion breakpoint occurrence rate.However, it is not suitable for identifying new fusion partners and may not be sensitive enough for low-abundance fusion transcripts. 45Therefore, it is not included in our recommended screening strategy.

Screening Recommendations for NRG1/2 Fusion
Despite advancements in detection methods, challenges remain in identifying NRG1 and NRG2 gene fusions.These include difficulties in detecting low-abundance fusion transcripts, the need for high-quality samples, lack of standardized methods, and low sensitivity for rare fusion events in heterogeneous tumors.
To enhance the identification of NRG1 gene fusion solid tumor patients, we recommend using DNA or RNA NGS panels targeting the intronic regions of NRG1/2, or pERBB3 immunohistochemistry as the primary screening strategy.RNA NGS technology is particularly recommended when histology and molecular subtypes are unclear.Specific detection strategies and workflow information were listed as follow (►Table 1; ►Fig. 2).

Treatment Strategies for NRG1/NRG2 Fusion
Currently, there are no approved targeted therapies specifically for the treatment of NRG1 and NRG2 fusions.However, several potential treatment strategies are being investigated in clinical trials.These include targeting NRG1 fusion solid tumors using TKIs, monoclonal antibodies, or immunotherapy.Due to the intricate molecular pathways associated with NRG1 fusion malignancies, novel therapeutic approaches that target specific mutations or signaling pathways have shown promise in preclinical studies and are currently being evaluated in clinical trials (►Table 2).

Pan-ERBB Tyrosine Kinase Inhibitors
There are several clinical targeted approaches for the treatment of NRG1 and NRG2 fusion tumors, with the inhibition of the ERBB2-ERBB3 heterodimer activity being considered the most effective method.

Afatinib
Afatinib, a pan-ERBB small molecule TKI, irreversibly inhibits tyrosine kinase autophosphorylation by binding to the kinase domains of EGFR, ERBB2, and ERBB4, leading to downregulation of the ERBB signaling.A case series report 46 included six cases of metastatic NRG1 fusion tumors treated with afatinib, comprising five cases of metastatic lung cancer (two mucinous adenocarcinoma and three nonmucinous adenocarcinoma) and one case of metastatic colorectal cancer.Among these cases, one patient with IMA carrying CD74-NRG1 fusion achieved partial remission for over 18 months after treatment with afatinib.Two patients with nonmucinous adenocarcinoma showed sustained responses for over 24 months.One patient with invasive lung mucinous adenocarcinoma carrying SDC4-NRG1 fusion initially achieved partial remission for 5 months with afatinib (40 mg/d), but later experienced lung progression.After increasing the dose of afatinib to 50 mg/d, the patient achieved another 6 months of partial remission.Additionally, one patient with metastatic colorectal cancer carrying POMK-NRG1 fusion and positive KRAS mutation achieved disease stability for 16 months with second-line treatment of afatinib. 46An alliance composed of 22 centers from 9 countries in Europe, Asia, and the United States provided data on pathologically confirmed NRG1 fusion lung cancer patients, showing an overall response rate (ORR) of 25% for afatinib, independent of the NRG1 fusion subtype, and a median progression-free survival of 2.8 months. 37Based on these study results, afatinib may be a treatment option for NRG1 fusion tumors.

Tarloxotinib
Tarloxotinib is a prodrug that undergoes cleavage under hypoxic conditions to release an effective and irreversible pan-ERBB inhibitor.It represents a novel therapeutic approach that targets the tumor-specific hypoxic environment for cancer treatment.In the MDA-MB-175vIII breast cancer cell line harboring DOC4-NRG1 fusion, tarloxotinib-E effectively inhibits the phosphorylation of ERBB2 and ERBB3 at concentrations similar to afatinib, while simultaneously suppressing the pERK1/2 and pAKT signals. 47The Phase II RAIN-701 trial, which investigates the use of tarloxotinib as a monotherapy, includes a treatment arm targeting NRG1 fusion tumors (NCT03805841).At present, the results of this subset have not been disclosed. 48

Seribantumab (MM-121, FTN-001)
Seribantumab is a fully human anti-ERBB3 IgG 2 monoclonal antibody.Preclinical experiments have shown that seribantumab inhibits the activation of ERBB3 signaling in cells carrying NRG1 gene fusions and disrupts the stability of the entire ERBB family signaling pathway, including the activation of ERBB2, EGFR, and ERBB4. 49Results from an ongoing Phase II clinical trial, CRESTONE (NCT04383210), evaluating the use of seribantumab in NRG1 fusion-positive solid tumors, demonstrated an ORR of 33% across all cancer types, including two complete responses and a disease control rate of 92%. 50

Lumretuzumab
Lumretuzumab, a polyethylene glycol-engineered humanized monoclonal antibody developed by Roche, aims to inhibit the activation and signal transduction of ERBB3. 51n cellular experiments using SLC3A2-NRG1 fusion-positive HEK293T cells, lumretuzumab can inhibit the formation of ERBB2/ERBB3 heterocomplex induced by SLC3A2-NRG1 fusion, thereby suppressing the activation of the PI3K/ERK/ mTOR signaling pathway and the proliferation and growth of tumor cells. 52

ERBB2/ERBB3 Selective Bispecific Monoclonal Antibodies
The ERBB2/ERBB3 bispecific monoclonal antibody, known as zenocutuzumab, targets both ERBB2 and ERBB3 receptors.By doing so, it effectively blocks the activation of ERBB3 by NRG1 fusion protein and inhibits the formation of heterodimers between ERBB2 and ERBB3.This mechanism of action has shown significant efficacy in patients with NRG1 fusion.

Zenocutuzumab (MCLA-128)
Zenocutuzumab is a bispecific human IgG 1 antibody that contains two separate Fab arms specifically targeting the extracellular domains of ERBB2 and ERBB3.It can simultaneously inhibit the interaction between ERBB2 and NRG1, as Expert Consensus on NRG1/2 Fusion in Solid Tumors Xu et al. 93 well as the heterodimerization between ERBB3 and EGFR.This dual inhibition prevents ERBB3 and ERBB2 heterodimerization. 53In a clinical trial involving NRG1 fusion-positive/ estrogen receptor-positive breast cancer patients who had experienced disease progression after treatment with cyclin-dependent kinase 4/6 inhibitors, zenocutuzumab  Expert Consensus on NRG1/2 Fusion in Solid Tumors Xu et al. 95

Drug Resistance
NRG1 fusion has been identified as a potential mechanism of resistance to targeted therapies.For example, in breast cancer cell lines treated with lapatinib, increased expression of NRG1 has been associated with acquired resistance to EGFR and ERBB2 kinase inhibitors.Overexpression of NRG1 leads to reactivation of EGFR, ERBB2, and ERBB3 through phosphorylation.However, the combination of pertuzumab and lapatinib can inhibit NRG1-induced signaling more effectively than either drug alone.In animal models, this combination therapy has shown greater tumor regression compared with single-drug treatments. 56Similarly, in selective inhibitors of nuclear export (SINE)-resistant ovarian cancer cell lines, the NRG1/ERBB3 pathway is upregulated.
The antitumor effect of SINE can be restored by removing ERBB3 using siRNA. 57Additionally, exogenous NRG1 can reduce the antitumor effect of SINE in ovarian cancer cell lines with high ERBB3 expression.In ALK-rearranged lung cancer, activation of the NRG1-ERBB3 axis can cause resistance to lorlatinib. 58However, pharmacological inhibition of ERBB3 or knockdown of the ERBB3 gene can restore sensitivity to lorlatinib in lung cancer cell lines.These findings suggest that targeting the NRG1/ERBB3 axis may be a potential treatment option for resistant cancers.However, it is important to consider the ecological balance between ERBB receptors, as NRG1 can bind to different receptors and unrestricted activation of other ligand-receptor axes may contribute to resistance.Therefore, future drug selection should aim to comprehensively inhibit the ERBB family signaling. 38

Summary and Prospect
Tumor-driven fusion protein targets are highly valuable in targeted drug research.The significance of NRG1 fusion in carcinogenesis was initially recognized in the mid-2010s, despite being first reported in breast cancer cell lines in 1997.The recent discovery of NRG2 fusion further emphasizes its importance.
To detect fusion variants of NRG1 and NRG2 genes, particularly in their intronic regions, we propose RNA-based NGS technology, specifically WTS, as the optimal method.Comprehensive molecular profiling analysis of NRG1 and NRG2 fusion solid tumor patients can then identify potential therapeutic targets and guide personalized treatment strategies.This analysis can be achieved through NGS and other advanced genomic technologies.Alternatively, in cases where this is not feasible, IHC detection of pERBB3 levels can serve as a costeffective preliminary screening method for NRG1 fusion.
Understanding the molecular mechanisms and signaling pathways affecting NRG1 and NRG2 fusion genes is crucial for developing effective treatment strategies.Targeted therapies against these gene variants and signaling pathways have shown promising results in preclinical studies and early clinical trials.Drugs targeting the binding of NRG1 to ERBB3 and/or the heterodimerization of ERBB2/ERBB3, such as the bispecific monoclonal antibody zenocutuzumab, have demonstrated tumor volume reduction in NRG1 fusion-positive tumors.These findings confirm that NRG1 and NRG2 gene fusions, although rare in solid tumors, are actionable oncogenic mutations.Patients who are NRG1 positive and have failed standard treatment are recommended to participate in relevant clinical trials to increase their chances of benefiting.
In conclusion, the management of NRG1 and NRG2 fusion solid tumors necessitates a multidisciplinary approach that encompasses molecular detection methods, targeted therapies, and the selection of combination therapies.Further research and clinical trials are warranted to explore the most effective strategies for addressing these intricate malignancies.

Fig. 1
Fig. 1 NRG1 and NRG2 structures.(A) NRG1 possesses I, II, and III subtype structures patterns.The coding sequences of the same isoform vary due to diverse transcription start sites and alternative splicing of NRG1 gene promoters.It is worth noting that the EGF-like domain alone has the capability to efficiently activate homologous ERBB receptor tyrosine kinases.N and C marked in red represent the N-terminal and C-terminal of NRG1 protein, respectively.To obtain further information, please refer to the relevant literature. 2,38(B) NRG2 structure.CRD, cysteine-rich domain; CTc, cytoplasmic tail domain C terminal of the EGF-like domain; TMc, transmembrane domain C terminal of the EGF-like domain; TMn, transmembrane domain N-terminal of the EGF-like domain.

Table 1
Consensus on the diagnosis and treatment of NRG1/2 gene fusion solid tumors NRG1/2 gene fusion test, in parallel to other actionable oncogenic drivers' tests is recommended for every adult and pediatric patient with advanced or metastatic solid tumor at diagnosis.NGS testing contain NRG1/2 gene fusions is strongly recommended for invasive mucinous lung adenocarcinoma confirmed by histopathology The main methods for NRG1/2 gene fusion testing are whole transcriptome sequencing (WTS), RNA-based NGS panels, and DNA-based NGS panels covering the intronic regions of NRG1/2.The selection of testing platforms and methods should be made reasonably based on sample type, tumor cell content, specimen quality, platform accessibility, testing turnaround time, and cost.RNA-based NGS panels have higher sensitivity than DNA-based NGS panels.If necessary, multiple platforms can be used for complementation and verification, especially when IHC results are positive and DNA-based NGS panel results are negative.In such cases, it is strongly recommended to use the third detection method, RNA-based NGS panel, for confirmation Fusion in Solid Tumors Xu et al.

Table 2
Drugs under development for target NRG1 fusion locally advanced or metastatic solid tumors (clinicaltrials.govaccessed on August 1, 2023)